Recent news on

Chamber Announces 8 Kruesi Award Honorees, 4 Early Innovator Finalists  -  Mar 30, 2007
The Chattanoogan,Glenveigh Pharmaceuticals, Inc. has discovered a new use for an existing drug (digoxin immune FAB ovine) to treat preeclampsia, a pregnancy disease that

Protherics puts DigiFab up for Canadian approval  -  18 Jan 2007
Pharma Times (subscription),The company noted that DigiFab (digoxin immune fab) is the leading treatment of its type in the USA, where it is approved for the treatment of

Protherics PLC announces Regulatory Application  -  Jan 7, 2007
Genetic Engineering News (press release),DigiFabTM contains purified ovine polyclonal antibody fragments and each vial of DigiFabTM, which contains 40 mg of digoxin immune Fab, will bind

Protherics' DigiFab(TM) to replace Digitalis Antidot(R) in Europe  -  Nov 28, 2006
PipelineReview.com (press release),The final product is freeze dried, and each vial of DigiFabTM, which contains 40 mg of digoxin immune Fab, will bind approximately 0.5 mg digoxin.

Protherics' DigiFab(TM) to replace Digitalis Antidot(R) in Europe  -  Nov 28, 2006
PipelineReview.com (press release),The final product is freeze dried, and each vial of DigiFabTM, which contains 40 mg of digoxin immune Fab, will bind approximately 0.5 mg digoxin.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional